Please login to the form below

Not currently logged in
Email:
Password:

GSK to produce A (H1N1) vaccine stockpile

Following a WHO announcement of 9,830 reported cases of H1N1 flu; GSK said that it has orders from several governments to create a stockpile of a new vaccine

With the World Health Oganisation (WHO) announcing today that 40 countries have reported 9,830 cases of A (H1N1) flu, GlaxoSmithKline (GSK) said that it has orders from several governments to create a stockpile of a new A (H1N1) vaccine.

GSK expects to manufacture a candidate A (H1N1) adjuvanted influenza vaccine once virus seed is made available by the WHO. First doses of the vaccine are likely to be available four to six months later.

GSK has received interest from several governments aiming to stockpile the vaccine as a precautionary measure, including requests for 60m for the UK; 50m for France; 12.6m for Belgium and 5.3m for Finland.

The new candidate vaccine will require regulatory approval. However, registration should be expedited because in 2008 GSK received a European licence for a pandemic vaccine based on a 'mock-up' dossier. This approval was based on data involving the H5N1 influenza strain.

In clinical studies based on the H5N1 strain, an adjuvanted formulation has been shown to stimulate a higher immune response while using a smaller amount of antigen as compared to a formulation without adjuvant. The adjuvant system helps to increase the number of vaccines doses that can be produced and clinical studies show that it provides potential to offer protection even if the influenza strain changes slightly.

GSK has made substantial investments to expand capacity for its adjuvant system.  

20th May 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics